Alix Engalytcheff

Alix Engalytcheff is a seasoned professional with extensive experience in market access and strategy within the pharmaceutical industry. Currently serving as an Associate Principal at ZS since November 2022, Alix previously held pivotal roles at UCB, including Global Head of Access Capability and Global Market Access Strategy Lead, overseeing patient access strategies for romosuzumab in collaboration with Amgen. Prior experience includes Global Head of Access Strategy Immunology at AbbVie and Market Access Director for Western Europe and Canada. Alix also contributed to public affairs at Genzyme and held a Market Access Manager position at Schering-Plough. An accomplished academic, Alix served as an Assistant Professor in Analytical Chemistry at UCL and holds a Ph.D. and Pharm.D. from Université catholique de Louvain, along with training from Hepami in health economics.